Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments

Woonbok Chung, Jolanta Bondaruk, Jaroslav Jelinek, Yair Lotan, Shoudan Liang, Bogdan Czerniak, Jean Pierre J Issa

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Background: Bladder cancer (BCa) remains a lethal malignancy that can be cured if detected early. DNA hypermethylation is a common epigenetic abnormality in cancer that may serve as a marker of disease activity. Methods: We selected 10 novel candidate genes from the most frequently hypermethylated genes detected by DNA microarray and bisulfite pyrosequencing of bladder cancers and applied them to detect bladder cancer in urine sediments. We analyzed DNA methylation in the candidate genes by quantitative methylation-specific real-time PCR (qMSP) to detect bladder cancer in urine sediments from 128 bladder cancer patients and 110 age-matched control subjects. Results: Based on a multigene predictive model, we discovered 6 methylation markers (MYO3A, CA10, SOX11, NKX6-2, PENK, and DBC1) as most promising for detecting bladder cancer. A panel of 4 genes (MYO3A, CA10, NKX6-2, and DBC1 or SOX11) had 81% sensitivity and 97% specificity, whereas a panel of 5 genes (MYO3A, CA10, NKX6-2, DBC1, and SOX11 or PENK) had 85% sensitivity and 95% specificity for detection of bladder cancer (area under curve = 0.939). By analyzing the data by cancer invasiveness, detection rate was 47 of 58 (81%) in non-muscle invasive tumors (pTa, Tis, and pT1) and 62 of 70 (90%) in muscle invasive tumors (T2, T3, and T4). Conclusions: This biomarker panel analyzed by qMSP may help the early detection of bladder tumors in urine sediments with high accuracy. Impact: The panel of biomarker deserves validation in a large well-controlled prospectively collected sample set.

Original languageEnglish (US)
Pages (from-to)1483-1491
Number of pages9
JournalCancer Epidemiology Biomarkers and Prevention
Volume20
Issue number7
DOIs
StatePublished - Jul 2011

Fingerprint

DNA Methylation
Urinary Bladder Neoplasms
Biomarkers
Urine
Methylation
Genes
Neoplasms
Real-Time Polymerase Chain Reaction
Sensitivity and Specificity
Oligonucleotide Array Sequence Analysis
Epigenomics
Area Under Curve
Muscles
DNA

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. / Chung, Woonbok; Bondaruk, Jolanta; Jelinek, Jaroslav; Lotan, Yair; Liang, Shoudan; Czerniak, Bogdan; Issa, Jean Pierre J.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 20, No. 7, 07.2011, p. 1483-1491.

Research output: Contribution to journalArticle

Chung, Woonbok ; Bondaruk, Jolanta ; Jelinek, Jaroslav ; Lotan, Yair ; Liang, Shoudan ; Czerniak, Bogdan ; Issa, Jean Pierre J. / Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. In: Cancer Epidemiology Biomarkers and Prevention. 2011 ; Vol. 20, No. 7. pp. 1483-1491.
@article{4d0b26ec35884588973ff77092879564,
title = "Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments",
abstract = "Background: Bladder cancer (BCa) remains a lethal malignancy that can be cured if detected early. DNA hypermethylation is a common epigenetic abnormality in cancer that may serve as a marker of disease activity. Methods: We selected 10 novel candidate genes from the most frequently hypermethylated genes detected by DNA microarray and bisulfite pyrosequencing of bladder cancers and applied them to detect bladder cancer in urine sediments. We analyzed DNA methylation in the candidate genes by quantitative methylation-specific real-time PCR (qMSP) to detect bladder cancer in urine sediments from 128 bladder cancer patients and 110 age-matched control subjects. Results: Based on a multigene predictive model, we discovered 6 methylation markers (MYO3A, CA10, SOX11, NKX6-2, PENK, and DBC1) as most promising for detecting bladder cancer. A panel of 4 genes (MYO3A, CA10, NKX6-2, and DBC1 or SOX11) had 81{\%} sensitivity and 97{\%} specificity, whereas a panel of 5 genes (MYO3A, CA10, NKX6-2, DBC1, and SOX11 or PENK) had 85{\%} sensitivity and 95{\%} specificity for detection of bladder cancer (area under curve = 0.939). By analyzing the data by cancer invasiveness, detection rate was 47 of 58 (81{\%}) in non-muscle invasive tumors (pTa, Tis, and pT1) and 62 of 70 (90{\%}) in muscle invasive tumors (T2, T3, and T4). Conclusions: This biomarker panel analyzed by qMSP may help the early detection of bladder tumors in urine sediments with high accuracy. Impact: The panel of biomarker deserves validation in a large well-controlled prospectively collected sample set.",
author = "Woonbok Chung and Jolanta Bondaruk and Jaroslav Jelinek and Yair Lotan and Shoudan Liang and Bogdan Czerniak and Issa, {Jean Pierre J}",
year = "2011",
month = "7",
doi = "10.1158/1055-9965.EPI-11-0067",
language = "English (US)",
volume = "20",
pages = "1483--1491",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments

AU - Chung, Woonbok

AU - Bondaruk, Jolanta

AU - Jelinek, Jaroslav

AU - Lotan, Yair

AU - Liang, Shoudan

AU - Czerniak, Bogdan

AU - Issa, Jean Pierre J

PY - 2011/7

Y1 - 2011/7

N2 - Background: Bladder cancer (BCa) remains a lethal malignancy that can be cured if detected early. DNA hypermethylation is a common epigenetic abnormality in cancer that may serve as a marker of disease activity. Methods: We selected 10 novel candidate genes from the most frequently hypermethylated genes detected by DNA microarray and bisulfite pyrosequencing of bladder cancers and applied them to detect bladder cancer in urine sediments. We analyzed DNA methylation in the candidate genes by quantitative methylation-specific real-time PCR (qMSP) to detect bladder cancer in urine sediments from 128 bladder cancer patients and 110 age-matched control subjects. Results: Based on a multigene predictive model, we discovered 6 methylation markers (MYO3A, CA10, SOX11, NKX6-2, PENK, and DBC1) as most promising for detecting bladder cancer. A panel of 4 genes (MYO3A, CA10, NKX6-2, and DBC1 or SOX11) had 81% sensitivity and 97% specificity, whereas a panel of 5 genes (MYO3A, CA10, NKX6-2, DBC1, and SOX11 or PENK) had 85% sensitivity and 95% specificity for detection of bladder cancer (area under curve = 0.939). By analyzing the data by cancer invasiveness, detection rate was 47 of 58 (81%) in non-muscle invasive tumors (pTa, Tis, and pT1) and 62 of 70 (90%) in muscle invasive tumors (T2, T3, and T4). Conclusions: This biomarker panel analyzed by qMSP may help the early detection of bladder tumors in urine sediments with high accuracy. Impact: The panel of biomarker deserves validation in a large well-controlled prospectively collected sample set.

AB - Background: Bladder cancer (BCa) remains a lethal malignancy that can be cured if detected early. DNA hypermethylation is a common epigenetic abnormality in cancer that may serve as a marker of disease activity. Methods: We selected 10 novel candidate genes from the most frequently hypermethylated genes detected by DNA microarray and bisulfite pyrosequencing of bladder cancers and applied them to detect bladder cancer in urine sediments. We analyzed DNA methylation in the candidate genes by quantitative methylation-specific real-time PCR (qMSP) to detect bladder cancer in urine sediments from 128 bladder cancer patients and 110 age-matched control subjects. Results: Based on a multigene predictive model, we discovered 6 methylation markers (MYO3A, CA10, SOX11, NKX6-2, PENK, and DBC1) as most promising for detecting bladder cancer. A panel of 4 genes (MYO3A, CA10, NKX6-2, and DBC1 or SOX11) had 81% sensitivity and 97% specificity, whereas a panel of 5 genes (MYO3A, CA10, NKX6-2, DBC1, and SOX11 or PENK) had 85% sensitivity and 95% specificity for detection of bladder cancer (area under curve = 0.939). By analyzing the data by cancer invasiveness, detection rate was 47 of 58 (81%) in non-muscle invasive tumors (pTa, Tis, and pT1) and 62 of 70 (90%) in muscle invasive tumors (T2, T3, and T4). Conclusions: This biomarker panel analyzed by qMSP may help the early detection of bladder tumors in urine sediments with high accuracy. Impact: The panel of biomarker deserves validation in a large well-controlled prospectively collected sample set.

UR - http://www.scopus.com/inward/record.url?scp=79960101746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960101746&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-11-0067

DO - 10.1158/1055-9965.EPI-11-0067

M3 - Article

VL - 20

SP - 1483

EP - 1491

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 7

ER -